As of the time of writing, retatrutide has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, nor by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA)
They are collectively classified as proteopathies, which involve severe disruption in cellular protein homeostasis (proteostasis) associated with protein misfolding as well as disruptions in protein processing and localization (Chowhan et al., 2015)
Analytical verification procedures, including chromatographic purity profiling and mass spectrometry identity confirmation, are used to verify peptide identity, purity, and batch consistency
Importantly, doses below 500 IU every other day showed inferior results
As the founder of Auro Wellness and the only patent holder of transdermal glutathione, Dr